ResearcherNew York UniversityNo recent work listed
Berk Aykut
Matched on ORCID iD 0000-0001-8343-4258; OpenAlex author ID A5018989450. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 7
- Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-023-02606-9↗
- BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-022-02425-4↗
- Regulatory T Cells Keep Pancreatic Cancer at Bay. Co-author DOI 10.1158/2159-8290.cd-20-0002↗
- RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.10.006↗
- The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Co-author DOI 10.1158/2159-8290.cd-17-1134↗
- Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. First author DOI 10.1016/j.canlet.2014.12.037↗
- CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2014.217↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- George Miller · 5 shared papers, 2018–2023 · strength 0.53
- Paper Regulatory T Cells Keep Pancreatic Cancer at Bay. DOI 10.1158/2159-8290.cd-20-0002↗
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Deirdre Jill Cohen · 4 shared papers, 2018–2023 · strength 0.34
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. DOI 10.1158/2159-8290.cd-17-1134↗
- Gregor Werba · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. DOI 10.1158/2159-8290.cd-17-1134↗
- Brian E. Diskin · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. DOI 10.1158/2159-8290.cd-17-1134↗
- Wei Wang · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.10.006↗
- Joshua Leinwand · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.10.006↗
- Emma Kurz · 2 shared papers, 2018 · strength 0.10
- Thilo Welsch · 2 shared papers, 2015 · strength 0.10
- Nathalia A. Giese · 1 shared paper, 2015 · strength 0.06
- Christian Teske · 1 shared paper, 2015 · strength 0.06
- Miriam Schenk · 1 shared paper, 2015 · strength 0.06
- Donnele Daley · 1 shared paper, 2018 · strength 0.05
- Ryan B Sartor · 1 shared paper, 2018 · strength 0.05
- Deepak Saxena · 1 shared paper, 2018 · strength 0.05
- Smruti Pushalkar · 1 shared paper, 2018 · strength 0.05
- Xin Li · 1 shared paper, 2018 · strength 0.05
- Constantinos Pantelis Zambirinis · 1 shared paper, 2018 · strength 0.05
- Alejandro Torres-Hernandez · 1 shared paper, 2018 · strength 0.05
- Fei Li · 1 shared paper, 2018 · strength 0.05
- Philip A. Harris · 1 shared paper, 2018 · strength 0.05
- Atsuo Ochi · 1 shared paper, 2018 · strength 0.05
- Marcin Teodorczyk · 1 shared paper, 2015 · strength 0.04
- Wilko Weichert · 1 shared paper, 2015 · strength 0.04
- Martin Ronald Sprick · 1 shared paper, 2015 · strength 0.04
- Andreas Trumpp · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.